{"id":6100,"date":"2025-03-22T17:44:37","date_gmt":"2025-03-22T14:44:37","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6100"},"modified":"2025-03-22T17:44:37","modified_gmt":"2025-03-22T14:44:37","slug":"key-takeaways-5-year-data-on-tavr-for-failing-surgical-valves","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/key-takeaways-5-year-data-on-tavr-for-failing-surgical-valves\/","title":{"rendered":"Key Takeaways: 5-Year Data on TAVR for Failing Surgical Valves"},"content":{"rendered":"<div>Key Takeaways: 5-Year Data on TAVR for Failing Surgical Valves<\/div>\n<div><\/div>\n<div>The data were presented as a late-breaker at the Cardiovascular Research Technologies (CRT) 2025 conference this month.<\/div>\n<div><\/div>\n<div><span> \u2022 Positive 5-Year Outcomes: The PARTNER 3 Aortic Valve-in-Valve Registry showed 11% mortality at five years, supporting TAVR as a viable option for failing bioprosthetic valves.<\/span><\/div>\n<div><span> \u2022 Study Population: 100 low- and intermediate-risk patients underwent transfemoral TAVR using the Sapien 3 valve.<\/span><\/div>\n<div><span> \u2022 Clinical Implications: Results may help expand TAVR eligibility beyond high-risk patients.<\/span><\/div>\n<div><span> \u2022 Lifetime Management Considerations: Younger patients receiving bioprosthetic valves may benefit from an SAVR-first approach, preserving future TAVR options.<\/span><\/div>\n<div><span> \u2022 Hemodynamics &amp; Optimization: Pressure gradients remained at 17-19 mmHg at five years. Surgical root enlargement and optimized valve sizing could improve long-term TAVR-in-TAVR feasibility.<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways: 5-Year Data on TAVR for Failing Surgical Valves The data were presented as a late-breaker at the Cardiovascular Research Technologies (CRT) 2025 conference this month. \u2022 Positive 5-Year Outcomes: The PARTNER 3 Aortic Valve-in-Valve Registry showed 11% mortality at five years, supporting TAVR as a viable option for failing bioprosthetic valves. \u2022 Study [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6100","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6100","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6100"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6100\/revisions"}],"predecessor-version":[{"id":6101,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6100\/revisions\/6101"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6100"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6100"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6100"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}